The short answer: in 2015, researchers from the University of Leeds and São Paulo State University showed that MP1, a small peptide from the venom of the Brazilian social wasp Polybia paulista, punches holes in artificial membranes that mimic the surface of cancer cells far more readily than in membranes that mimic healthy cells. It was laboratory work on model membranes, not a treatment, and no wasp-venom cancer drug exists. Later work suggests MP1 itself is too damaging to red blood cells to be given as it is, although modified versions are being explored.
Headlines at the time claimed the venom "kills cancer cells without harming healthy ones". Here is what the study actually found, why it attracted attention, and where the research stands now.
The wasp and its venom
Polybia paulista is a social paper wasp found in Brazil, especially around São Paulo, and in Paraguay and Argentina. It lives in large colonies that can grow from a few thousand to more than ten thousand wasps, with dozens of queens sharing a single nest. Like other wasps, it uses its sting for defence, and the venom contains a mixture of small peptides that cause pain, swelling and the breakdown of cells.
Polybia paulista. Photo: Prof. Mario Palma, São Paulo State University.
One of those peptides is a mastoparan called Polybia-MP1, or simply MP1. Mastoparans are short chains of amino acids that carry a positive charge and are drawn to cell membranes. In the wasp, MP1 is part of the venom's defensive and antimicrobial arsenal; earlier lab studies had already reported that it could inhibit the growth of prostate and bladder cancer cells and of leukaemia cells resistant to several drugs. (The image at the top of this page shows a common yellowjacket for illustration, not Polybia paulista.)
What the 2015 study tested
The research was published in the Biophysical Journal on 1 September 2015 under the title "PE and PS Lipids Synergistically Enhance Membrane Poration by a Host-Defense Peptide with Anticancer Properties". Rather than working with tumours, the team built simplified model membranes, bubbles of lipid in the lab, with compositions chosen to resemble either healthy cells or cancer cells.
The key ingredients were two lipids. In a healthy cell, phosphatidylserine (PS) and phosphatidylethanolamine (PE) sit mostly on the inner face of the membrane, facing the cell's interior. In many cancer cells, the arrangement is disturbed and these lipids appear on the outer surface too. Using imaging and biophysical measurements, the researchers found that PS and PE together made the membranes far more vulnerable to MP1: the peptide opened pores within seconds, and the holes were large enough for big molecules such as RNA and proteins to leak out.
A likely explanation is that negatively charged PS attracts the positively charged peptide, while PE makes the membrane easier to bend and open. The combination, the authors argued, could explain why MP1 had appeared to act selectively on cancer cells in earlier experiments.
Why researchers were excited
Most cancer drugs target proteins or DNA inside cells. Attacking the membrane itself is a different strategy, and in principle it could be harder for tumours to develop resistance to. Paul Beales of the University of Leeds, a co-author, suggested that therapies aimed at the lipid make-up of cancer cell membranes could become "an entirely new class of anticancer drugs".
He also pointed out that such a drug would most likely be used in combination with others, hitting different parts of a cancer cell at the same time. His colleague João Ruggiero Neto of São Paulo State University proposed that the selectivity comes from the unusual properties of cancer cell membranes. The study was funded by bodies including the European Commission, the São Paulo Research Foundation and the UK's Engineering and Physical Sciences Research Council.
What the study did not show
The original viral posts went far beyond the evidence. The 2015 paper did not test MP1 in people or animals, and it did not show that wasp venom cures cancer. A model membrane lacks almost everything a real tumour has: blood supply, surrounding tissue, the immune system and the many proteins in a real cell surface. The university's own news release said further work was needed to establish safety, and that the results were promising only at the laboratory stage.
Being stung by wasps is no way to treat cancer, and venom-based remedies sold online are not proven treatments. Anyone with questions about cancer treatment should talk to a doctor or an oncology team.
Where the research stands now
The Leeds group continued the work. A 2025 preprint describing new MP1-based peptides, which has not yet been peer-reviewed, reports that the original MP1 caused unacceptably high destruction of red blood cells at every dose tested and was not truly cancer-specific, ruling it out for injection into the bloodstream. To get around this, the researchers attached MP1 to a fragment that binds EGFR, a receptor common on some breast cancers, linked through a sequence that is cut by an enzyme (MMP-2) abundant around tumours.
In lab dishes, the modified peptide killed a breast cancer cell line rich in EGFR and MMP-2 while having little effect on non-cancerous breast cells, and it caused far less damage to red blood cells. In mice carrying human breast tumours, three intravenous doses slowed tumour growth, with final tumours about two-thirds the size of those in untreated animals. The groups were small and the work is still preclinical.
No membrane-attacking peptide of this kind is yet in routine clinical use, though a few related compounds have reached clinical trials. MP1 is best seen as a useful template from nature that scientists are re-engineering, not a finished medicine.
Venom as a source of medicines
Looking to venoms for drugs is not as strange as it sounds. Venom peptides have evolved to act powerfully on cell membranes, ion channels and receptors, which makes them attractive starting points. Honeybee venom's main component, melittin, is another membrane-disrupting peptide that has been studied in the lab; yet the same property that kills cells also makes such peptides toxic, which is why careful engineering and testing are needed before any reach patients.
The lesson of the MP1 story is a common one in science news: an elegant lab finding about how something works is an early step, not a cure. The wasp gave researchers a clue; turning that clue into a safe drug takes years of further work.
Sources: University of Leeds news release (September 2015); Biophysical Journal study; bioRxiv preprint (2025): EGFR-targeted, MMP-activated MP1 peptides; Wikipedia: Polybia paulista; Wikipedia: Melittin; originally reported by The Mind Unleashed. Wasp photo: Prof. Mario Palma.
Related:
IN Holy Quran القرآن الكريم ALLAH SUBHAN WA TALA SAYS: Your Lord revealed to the bees: "Build dwellings in the mountains and the trees, and also in the structures which men erect. Then eat from every kind of fruit and travel the paths of your Lord, which have been made easy for you to follow." From inside them comes a drink of varying colours, containing healing for mankind. There is certainly a Sign in that for people who reflect. (Qur'an, 16:68-69)
ReplyDelete